Skip to main content
OpenTrials
Completed

NCT Number: NCT06319300

Artificial Intelligence-assisted Insulin System in Type 2 Diabetes in General Wards

Our study was a single-blind, randomised, controlled, multicentre study. The study was planned to enrol 142 patients with T2DM admitted to general wards who required subcutaneous insulin therapy. Participants were randomly divided into two groups in the ratio of 1:1, one group with an artificial intelligence-assisted insulin decision system to adjust insulin doses for blood glucose control, and the other group received clinician-instituted insulin dose adjustments for blood glucose control. The effectiveness and safety of the system was confirmed by comparing the glycaemic control and risk of adverse events between the two groups.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, 200032, China

About this study

Our study was a single-blind, randomised, controlled, multicentre study. The study was planned to enrol 142 patients with T2DM admitted to the general ward who required subcutaneous insulin therapy. Participants were randomly divided into two groups in the ratio of 1:1, one group with an artificial intelligence-assisted insulin decision system to adjust insulin doses for blood glucose control, and the other group received clinician-instituted insulin dose adjustments for blood glucose control. The effectiveness and safety of the system was confirmed by comparing the glycaemic control and risk of adverse events between the two groups.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of type 2 diabetes mellitus > 3 months
  • Age≥18 years old
  • Receiving glucose-lowering management for at least 90 days
  • Blood glucose:7.8-22.2 mmol/L
  • Length of proposed hospitalisation ≥5 days.

Exclusion criteria

  • Type 1 diabetes mellitus, other special types of diabetes mellitus
  • BG>22.2 mmol/L, or acute complications of diabetes, such as diabetic ketoacidosis, diabetic hyperosmolar state
  • History of severe or repeated hypoglycaemia
  • BMI≥45 kg/m2
  • Pregnant and lactating women
  • Clinically relevant liver disease (established cirrhosis and portal hypertension)
  • Presence of severe renal disease (serum creatinine ≥3.0 mg/dL or estimated glomerular filtration rate <30 ml/min/1.73 m2)
  • Severe cardiac insufficiency
  • Patients undergoing corticosteroid therapy (equivalent to a prednisone dose >5 mg/day)
  • Psychiatric abnormalities or impaired cognitive function
  • Patients with severe oedema, infection, or peripheral blood circulation disorder
  • Patients with severe illness or patients to be transferred to ICU for treatment
  • Surgery of the heart or abdomen that may have a significant impact on the test is planned during hospitalisation
  • Expected to be NPO for an extended period
  • Any medical or psychological conditions, or medications that, in the doctor's judgment, could interfere with the results
  • Subjects who cannot comply with the protocol.

Treatment and study plan

AI-assisted insulin dose adjustment model

Device

We use an artificial intelligence-assisted insulin dose adjustment system to adjust insulin doses in hospitalised patients

Other names: the Artificial Intelligence-assisted Insulin Dose Adjustment System

doctor's insulin dose adjustment

Other

participants' insulin doses are adjusted by doctors

Primary outcomes

  1. time in target range (3.9-10.0 mmol/L )

    Time frame: ≥3 days

    Proportion of time in the target glucose range (TIR; 3.9-10.0 mmol/L) measured by CGM during the intervention period.

Secondary outcomes

  1. sensor glucose

    Time frame: ≥3 days

    Proportion of time during which sensor glucose levels are within the ranges (5.6-10.0mmol/L,10.1-13.9mmol/L, >13.9mmol/L,<3.0mmol/L, 3.0-3.8mmol/L), as measured by CGM during the intervention period

  2. capillary blood glucose

    Time frame: ≥3 days

    pre-breakfast, pre-lunch, pre-dinner, pre-bedtime

  3. hypoglycaemic event

    Time frame: ≥3 days

    capillary blood glucose<3.9 mmol/L, <3.0 mmol/L, < 2.2 mmol/L or an episode that requires of assistance of another person

  4. hyperglycaemic event

    Time frame: ≥3 days

    capillary blood glucose>20.0 mmol/L, and/or ketoacidosis, and/or hyperosmotic status.

  5. insulin dosage

    Time frame: ≥3 days

    insulin dosage

  6. satisfaction score of doctors

    Time frame: after intervention

    evaluated by questionnaire.

  7. Length of hospitalisation

    Time frame: ≥3 days

    Length of hospitalisation

  8. Other/Serious Adverse Events

    Time frame: ≥3 days

    Itchy skin, admission to ICU, death, etc.

Sponsors and collaborators

Lead sponsor

Shanghai Zhongshan Hospital

Other

Collaborators

  • Shanghai Fifth People's Hospital

Registry information

Official study title

Efficacy and Safety of the Artificial Intelligence-assisted Insulin Dose Adjustment System for Glycaemic Control in Patients With Type 2 Diabetes Mellitus in General Wards: a Multicentre, Single-blind, Randomised Controlled Study

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Mar 20, 2024
Registry last updated
Jun 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.